xMD

Baltimore, United States Founded: 2015 • Age: 11 yrs
Laboratory instruments and consumables are developed for life science research.

About xMD

xMD is a Healthcare company based in Baltimore (United States) founded in 2015. Laboratory instruments and consumables are developed for life science research. xMD has raised $775 thousand across 4 funding rounds from investors including SBIR and TEDCO. xMD offers products and services including Laboratory Instruments and Consumables. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is x MD Diagnostics, Inc. Its competitors include 10X Genomics, Cepheid and Fluidigm; 3 of its 3 listed competitors have raised funding.

Company details

xMD was founded in 2015 and is headquartered in Baltimore, United States. Focus is placed on molecular diagnostics tools for research, biopharmaceutical, and clinical laboratory sectors. Proprietary Expression Microdissection technology is employed to isolate, procure, and enrich specific cells from biopsy and specimen samples. Operations center on providing instruments and consumables that support diagnostics in life sciences.

  • Headquarters Baltimore, United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website xmddiagnostics.com
  • Legal Name X Md Diagnostics, Inc.
Key Metrics
  • Total Equity Funding
    $775K (USD)

    in 4 rounds

  • Latest Funding Round
    $256K (USD), Grant

    Aug 2021

  • Investors
    SBIR

    & 1 more

Products & Services of xMD

xMD offers a comprehensive portfolio of products and services, including Laboratory Instruments and Consumables.

Laboratory Instruments
Diagnostic Tools

Devices for automating molecular testing in labs

Consumables
Diagnostic Supplies

Materials for precision diagnostics and sample enrichment

Funding Insights of xMD

xMD has successfully raised a total of $775K across 4 strategic funding rounds. The most recent funding activity was a Grant round of $256 thousand completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $775,000
  • Total Rounds 4
  • Last Round Grant β€” $256,000
  • First Round $175,000

    (Mar 2017)

  • Investors Count 2

All 4 funding rounds of xMD with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2021$256,000Grant––
Oct 2018$500,000Seed––
–
Dec 2017$100,000Seed––
Mar 2017$175,000Seed––
–
Valuation history

2 investors in total: 2 institutional.

Investors in xMD

xMD has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include SBIR and TEDCO.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital fund and startup accelerator programs focused on seed and early stage companies
1998tedcomd.comColumbia, United States
Federal innovation and scientific achievement services are provided.
1982sbir.govLithia Springs, United States
Premium access

Investor details for xMD

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of xMD

4 people are tracked at xMD (4 in leadership).

NameRoleGroup
Nicole Massoll
Medical Director, PathologistLeadership
Ting Pau Oei
CEO & Co-ChairmanLeadership
Benjamin Shapiro
Co-Founder & Chief Scientific OfficerLeadership
Stephen Ritterbush
CFO & Co-ChairmanLeadership
Premium access

Complete people profiles for xMD

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of xMD

3 dated milestones of xMD across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded xMD is founded.
  2. Funding First funding round of $175K.
  3. Funding Latest funding round, Grant, of $256K.

Competitors of xMD

xMD has 3 listed competitors in our database, 3 of them funded. They include 10X Genomics, Cepheid and Fluidigm.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
10xgenomics.com2012Pleasanton, United States$199.9M961
Instrument systems for genomic research and sequencing libraries are developed.
cepheid.com1996Sunnyvale, United States$19.1M1,299
Developer of molecular diagnostic testing solutions
fluidigm.com1999San Francisco, United States$40.53M205
Instruments for life sciences research and applications are developed.
Premium access

Detailed competitors of xMD

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of xMD

The website of xMD (xmddiagnostics.com) receives about 1.5K visits a month.

  • Monthly visits
    1.5K

    ▼ 18.7% vs previous month

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as xMD (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about xMD

xMD was founded in 2015 and raised its 1st funding round 2 years after it was founded.

xMD is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.

xMD is a funded company, having raised a total of $775K across 4 funding rounds to date. The company's 1st funding round was a Seed of $175K, raised on Mar 2017.

xMD was founded in 2015 and is headquartered in Baltimore, United States. Focus is placed on molecular diagnostics tools for research, biopharmaceutical, and clinical laboratory sectors. Proprietary Expression Microdissection technology is employed to isolate, procure, and enrich specific cells from biopsy and specimen samples. Operations center on providing instruments and consumables that support diagnostics in life sciences.

xMD's top competitors include Cepheid, 10X Genomics and Fluidigm.

xMD offers Laboratory Instruments and Consumables.

xMD has 2 investors. Key investors include SBIR, and TEDCO.

xMD operates through X Md Diagnostics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available